need patient
extend model near-term busi momentum
remain cloudi note estimate consensu
long-term project world-wide consum healthcar
year organ revenue compound-annual-growth-rate line
expect steep sequenti declin ep wors
histor sequenti perform lower ep
con estim
sequenti recal management previous caution weaker
due loss exclus gandrogel convey us
ep ep impli ep base
guidanc midpoint hope prove conserv also
note management guidanc includ anticip acquisit
ranir
sever model adjust follow may analyst day adjust
revenu project total revenu essenti unchang
includ revenu ranir assum acquisit
close end excl anim health revenue gener
csca segment revenue note management guidanc rang
includ ranir rais
includ ranir updat ep project
follow guidanc
management guidanc exclud contribut
accret ranir acquisit assum close increment cost
save initi gproair model
rx exit lack clariti specif action time
extend model project compound-annual-growth-rate revenue
ep mention project boost yoy
full year contribut acquisit ranir start
base project compound-annual-growth-rate revenue ep
valuat perspect may management estim impact net dilut
appreci support
institut investor all-america
research survey request ballot
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
plan rx exit assum sale valuat
assum spin note management provid assumpt
includ broader price collus lawsuit gener
manufactur gener drug stock valuat fell unclear
lawsuit resolv predict potenti penalti
frame simplist pt valuat scenario plu caveat valuat given
rx spin use management project ep would
exclud potenti equiti spin-off valu sharehold
estim due lack clariti enterpris valu amount debt
associ spin appli hypothet multipl
remain compani would impli pt
view rx sale bull case rx sale use management project assum
valuat ep would appli hypothet
multipl would impli pt note although
management indic hope gener industri valuat
step recent due govern gener price fix
caveat valuat face tax claim ireland ir total
disput tax claim situat may
resolv number year put number perspect
hypothet liabil would boost net debt march
increas current ev/ebita
repres estim two-year combin
oper cash flow section overview tax claim disput
background
pt explain pt base ep
howev current ep still includ rx busi mention
execut rx spin ep would base
management guid net dilut multipl would impli pt
still discount consum compani price-to-earnings think
reason given substanti tax liabil overhang brand
consum compani typic trade market premium due intrins
valu durabl brand yet demonstr organ
growth lever consum
level dividend yield still
consum compani
pt base ep target price-to-earnings discount
mean lower end standard
deviat rang con ntm ep
pipelin drive earn upsid multipl expans rx exit creat
sharehold valu new launch drive ep expect
multipl increas consum segment perform better expect margin
sharehold valu receiv favor outcom regard irish
tax file issu stock re-rat higher
deliv result line expect growth prospect
remain cloudi manag execut well improv csci
segment perform return modest growth rel
new launch disappoint busi pressur worsen rx exit value-
destruct us consum rx declin new launch delay
competit pressur worsen deterior margin profil drive ep
downsid rx exit hurt sharehold valuat due dis-synergi low
valuat receiv neg outcom regard irish tax file
issu stock multipl contract
revenu margin pipelin prospect
project modest revenu
earn growth come year
organ compound-annual-growth-rate revenu
option given new ceo board
north american store-brand
counter medicin adj op incom
intern consum over-the-counter adj
op incom franchis omega
manag work turn around
prescript rx gener adj op
incom leader gener topic limit
competit gener nich high
corpor overhead adj op
quarterli result guidanc updat
gproair launch
risk achiev price
new product launch delay
new invest spend enhanc
prospect higher anticip
dilut associ rx exit wors
expect
neg newsflow rx price collus
investig recal offic
examin fbi year ago part
investig
overview tax claim disput
resolut tax liabil overhang like take year may
investor day ask timing/expect resolut on-going
tax liabil cfo silcock state year away mean say year
two year away five six seven year away potenti
someth possibl realli specul point
background ir tax overhang
heel irish tax demand excl potenti interest
penalti disclos dec disclos april ir
seek payment relat athena neurosci april
receiv revis notic propos adjust nopa ir audit athena
neurosci acquir tax year state
nopa base irss construct event propos payment
repres addit tax penalti amount exclud
consider offset tax attribut nol potenti materi interest
compani also state pursu option incl potenti us-
ireland incom tax treati allevi doubl taxat
nopa relat transfer price posit ir audit athena
nopa assert took futur fund athena in-process
paid substanti higher royalti rate right exploit
rate base financi data contain origin purchas price alloc done
propos incom adjust gener appli
royalti rate tysabri sale revenu
strongli disagre ir incom posit compani convey
three rout resolv issu appeal ir offic appeal
explor mutual agreement procedur engag discuss ireland us
achiev resolut litig issu via us tax court system compani
indic option could take year time perspect
separ recal appeal irish high court irish tax
liabil issu expect substant hear held late
decis late earli state irish revenu
assess conflict long-standing year tax treatment
pharma legitim expect pursu
feb flag ir tax risk quantifi
potenti liabil state current involv sever audit adjust
relat disput includ litig ir includ litig regard
tax year well propos audit adjust relat litig cost
transfer price posit relat athena neurosci subsidiari acquir
tax year
background irish tax demand
publish dec state compani time file
appeal irish tax appeal commiss regard noa issu irish
offic revenu commission irish revenu year end dec
noa date nov assess irish corpor tax liabil worth
eur equival usd exclud interest applic penalti
noa relat tax treatment sale pharma acquir
tysabri intellectu properti relat asset biogen idec april
essenti up-front payment conting payment receiv
subsequ year recogn trade incom pharma tax return file
irish revenu oct two month expiri
applic five year statutori limit period irish revenu issu audit find
claim ip sale transact incl sale tysabri part
trade pharma therefor treat chargeabl gain
subject effect tax rate rather tax rate applic trade
incom amount receiv respect tysabri transact
relat transact enter rpi financ trust tax
strongli disagre basi pharma assess
methodolog use calcul amount set noa state
firmli believ noa without merit irish revenu
posit incorrect matter law also believ base applic
case law irish revenu publish guidanc constitut trade irish tax
purpos relat publish preced pharma tax return file
correctli approx year pharma consist file irish corpor
tax return basi carri trade acquir develop hold
exploit deal dispos intellectu properti right licens use
pharmaceut industri point numer exampl prior dispos
right treatment tax purpos disput irish
revenu accordingli time appeal noa pursu avail
administr judici avenu may necessari appropri
exhibit us spec brand gx comp sheet
us specialti brand gener
price
price
spec brand gx mean
spec brand gx median
valuat methodolog risk associ price target rate
recommend referenc research report pleas contact client support
follow us/canada hong kong latin
sydney tokyo altern may contact
invest repres morgan stanley research broadway attent
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
author report act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig talent trial locat juri composit judg
composit investor contact legal advisor issu law relat
subject matter materi
